[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13-16,34.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13-16,34.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
点击复制

Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第1期
页码:
13-16,34
栏目:
出版日期:
2016-01-25

文章信息/Info

Title:
Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism
作者:
梁雯丽1;  郑艳2;  李娜1;  赵德善1
1. 030001 太原, 山西医科大学第二医院核医学科;
2. 471000 洛阳, 河南科技大学第一附属医院核医学科
Author(s):
Liang Wenli1;  Zheng Yan2;  Li Na1;  Zhao Deshan1
1. Department of Nuclear Medicine, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China;
2. Department of Nuclear Medicine, the First Affiliated Hospital of Henan University of Science & Technology, Luoyang 471000, China
关键词:
格雷夫斯病; 甲状腺功能亢进症; 碘放射性同位素; 免疫球蛋白类; 甲状腺刺激; 受体; 促甲状腺素释放激素
Keywords:
Graves disease; Hyperthyroidism; Iodine radioisotopes; Immunoglobulins; thyroid-stimulating; Receptors; thyrotropin-releasing hormone
DOI:
10.3760/cma.j.issn.1673-4114.2016.01.003
摘要:
目的 探讨和分析131I治疗Graves甲亢后早期促甲状腺素受体抗体(TRAb)和甲状腺刺激抗体(TSAb)的变化及其相关性。方法 随机选择了89例Graves甲亢患者,其中,未行131I治疗的47例患者为对照组,131I治疗后3个月的42例甲亢患者为观察组。两组患者均进行了血清游离三碘甲状腺原氨酸(FT3)、血清游离甲状腺素(FT4)、TSH、TRAb、TSAb和甲状腺刺激阻断性抗体(TSBAb)的测定。FT3、FT4、TSH采用化学发光法测定。TRAb采用放射受体分析法测定。TSAb、TSBAb采用酶联免疫法测定。结果 观察组和对照组中的TRAb阳性率分别为78.6%(33/42)和36.2%(17/47);TSAb、TSBAb阳性率分别为38.1%(16/42)、0(0/42)和53.2%(25/47)、6.4%(3/47);TSAb与TRAb均为阳性的病例数分别为13例、15例;TSBAb为阳性的病例数分别为0例和3例,其中3例TSBAb阳性的患者,2例伴有TSAb和TRAb阳性,1例伴有TSAb阳性和TRAb阴性。结论 131I治疗后3个月时,多数Graves甲亢患者的血清TRAb异常增高;131I治疗后早期异常升高的TRAb只有部分(39.4%,13/33)显示TSAb增高,表明131I治疗后异常升高的TRAb多数并无TSAb功能。
Abstract:
Objective To investigate and analyze the changes of early thyroid stimulating hormone receptor antibody(TRAb) and thyroid stimulating antibody(TSAb) after 131I treatment for Graves hyperthyroidism and their correlation.Methods Eighty-nine patients with Graves hyperthyroidism were randomly selected in this study.The patients were divided into two groups:Group 1(control group):47 patients who did not receive 131I treatment;Group 2(study group):the remaining 42 patients who received 131I treatment before 3 months.Serum FT3,FT4,TSH,TRAb,TSAb,and TSBAb values were measured for all patients in two groups.FT3,FT4,and TSH valued were determined by chemiluminescence method.TRAb values were determined by radiation receptor analysis.TSAb and TSBAb values were determined by enzyme-linked immunosorbent assay.Results The positive rates of TRAb values in study group and control group were 78.6% and 36.2% respectively.The positive rates of TSAb and TSBAb values in study group and control group were 38.1%(16/42),0(0/42) and 53.2%(25/47),6.4%(3/47),respectively;the number of patients with positive TSAb and TRAb simultaneously in the study and control groups were 13(16 cases with positive TSAb and 33 cases with positive TRAb) and 15 cases(25 cases with positive TSAb and 17 cases with positive TRAb),respectively;the number of patients with positive TSBAb in the study and control groups were 0 and 3 cases,respectively.Two of three patients with positive TSBAb were positive TSAb and TRAb,simultaneously,1 of 3 patients with positive TSBAb were positive TSAb and negative TRAb.Conclusions The serum TRAb value in the majority of patients with Graves hyperthyroidism increased in 3 months after 131I treatment.The TSAb value in the part of patients with increased TRAb(39.4%,13/33) were abnormally high,showing that increased serum TRAb in 3 months after 131I treatment could not perform the same function as TSAb.

参考文献/References:

[1] Takamura Y,Nakano K,Uruno T,et al.Changes in serum TSH receptor antibody(TRAb) values in patients with Graves’ disease after total or subtotal thyroidectomy[J].Endocr J,2003,50(5):595-601.DOI:http://doi.org/10.1507/endocrj.50.595.
[2] Jang SY,Shin DY,Lee EJ,et al.Correlation between TSH receptor antibody assays and clinical manifestations of Graves’ orbitopathy[J].Yonsei Med J,2013,54(4):1033-1039.DOI:10.3349/ymj.2013.54.4.1033.
[3] Matthews DC,Syed AA.The role of TSH receptor antibodies in the management of Graves’ disease[J].Eur J Intern Med,2011,22(3):213-216.DOI:10.1016/j.ejim.2011.02.006.
[4] 冯凭.Graves病的诊断与治疗[J].国外医学:内分泌学分册,2004,24(1):68-69,72.DOI:10.3760/cma.j.issn.1673-4157.2004.01.026.Feng P.Diagnosis and treatment of Graces[J].Section Endocrinol Foreign Med Sci,2004,24(1):68-69,72.
[5] 钟兴祥,郑吉祥,蓝冠章,等.Graves甲亢131I治疗前后血清TRAb动态变化及临床价值[J].国际放射医学核医学杂志,2011,35(2):110-113.DOI:10.3760/cma.j.issn.1673-4114.2011.02.011.Zhong XX,Zheng JX,Lan GZ,et al.Changes of serum TRAb after 131I radiotherapy in patients of Graves hyperthyroidism[J].Int J Radiat Med Nucl Med,2011,35(2):110-113.
[6] Lantz M,Planck T,Asman P,et al.Increased TRAb and/or low anti-TPO titers at diagnosis of graves’ disease are associated with an increased risk of developing ophthalmopathy after onse[J].Exp Clin Endocrinol Diabetes,2014,122(2):113-117.DOI:10.1055/s-0033-1363193.
[7] Smith BR,Sanders J,Furmaniak J.TSH receptor antibodies[J].Thyroid,2007,17(10):923-938.DOI:10.1089/thy.2007.0239.
[8] Massart C,Sapin R,Gibassier J,et al.Intermethod variability in TSH-Receptor antibody measurement:implication for the diagnosis of graves disease and for the Follow-Up of graves ophthalmopathy[J].Clin Chem,2009,55(1):183-186.DOI:10.1373/clinchem.2008.115162.
[9] Costagliola S,Morgenthaler NG,Hoermann R,et al.Second Generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease[J].J Clin Endocrinol Metab,1999,84(1):90-97.DOI:http://dx.doi.org/10.1210/jcem.84.1.5415#sthash.3Zfyif5k.dpuf.
[10] Maugendre D,Massart C.Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves’ disease.Comparison with thyroid stimulating antibody bioassay[J].Clin Endocrinol(Oxf),2001,54(1):89-96.DOI:10.1046/j.1365-2265.2001.01197.x.
[11] Takasu N,Yamada T,Takasu M,et al.Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis[J].N Engl J Med,1992,326(8):513-518.DOI:10.1056/NEJM199202203260803.
[12] Takasu N,Oshiro C,Akamine H,et al.Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves’ patients and in 686 normal subjects[J].J Endocrinol Invest,1997,20(8):452-461.
[13] Kung AW,Lau KS,Kohn LD.Characterization of thyroid-stimulating blocking antibodies that appeared during transient hypothyroidism after radioactive Iodine therapy[J].Thyroid,2000,10(10):909-917.DOI:10.1089/thy.2000.10.909.
[14] Kamath C,Adlan MA,Premawardhana LD.The role of thyrotrophin receptor antibody assays in graves’ disease[J/OL].J Thyroid Res,2012:525936[2015-07-12].http://www.hindawi.com/journals/jtr/2012/525936/.DOI:10.1155/2012/525936.
[15] 张会娟,李道明,高冬玲,等.Graves病异常表达HLA-DR抗原的甲状腺上皮细胞与血清TSAb的关系[J].中华内分泌代谢杂志,2005,21(6):546-547.DOI:10.3760/j.issn:1000-6699.2005.06.023.Zhang HJ,Li DM,Gao DL,et al.Relationship between abnormal expression of HLA-DR antigen in thyroid epithelial cell and serum thyroid-stimulating antibodies in Graves’disease[J].Chin J Endocrinol and Metab,2005,21(6):546-547.
[16] Weetman AP.Thyrotoxicosis[J].Medicine,2013,41(9):540-545.DOI:10.1016/j.mpmed.2013.06.012.
[17] Yoshida K,Aizawa Y,Kaise N,et al.Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131I treatment for Graves’ disease[J].Clin Endocrinol(Oxf),1998,48(1):17-22.DOI:10.1046/j.1365-2265.1998.00330.x.

相似文献/References:

[1]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[2]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[3]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[4]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[5]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[6]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
　Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
[7]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[8]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
　WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[9]张建媛,缪蔚冰.电化学发光法与放射性受体分析法检测促甲状腺激素受体抗体的对比研究[J].国际放射医学核医学杂志,2012,36(1):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
　ZHANG Jian-yuan,MIAO Wei-bing.Comparative study between electrochemiluminescence immunoassay and radioactive receptor assay in measurement of serum thyrotropin receptor antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
[10]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
　HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
[11]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[12]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[13]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[14]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
　ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[15]孙琦婷,赵德善.Graves病甲状腺功能亢进症与血糖代谢[J].国际放射医学核医学杂志,2010,34(3):143.
　SUN Qi-ting,ZHAO De-shan.Graves disease hyperthyroidism and glycometabolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):143.
[16]袁卫红,张怡,罗志航.内分泌性眼病患者外周血中白细胞介素6和胰岛素样生长因子1水平变化的研究[J].国际放射医学核医学杂志,2008,32(3):167.
　YUAN Wei-hong,ZHANG Yi,LUO Zhi-hang.The investigation of cytokine level in peripheral blood of patients with thyroid eye disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(1):167.
[17]覃伟武.131Ⅰ治疗非Graves’甲状腺功能亢进及非毒性甲状腺肿后诱发Graves’病[J].国际放射医学核医学杂志,2006,30(6):325.
　QIN Wei-wu.Induction of Graves’ disease in patients with non-autoimmune hyperthyroidism or nontoxic goiter after radioiodine treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(1):325.
[18]赵炎,王俊起,沈婕.Graves病的131I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析[J].国际放射医学核医学杂志,2017,41(6):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]
　Zhao Yan,Wang Junqi,Shen Jie.131I therapy versus antithyroid drugs in Graves’ disease:a meta-analysis of randomized controlled trials[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]

备注/Memo

备注/Memo:
收稿日期:2015-07-16;改回日期:。
通讯作者:赵德善
更新日期/Last Update: 1900-01-01